Novartis AG (NVS)
NYSE: NVS · Real-Time Price · USD
130.44
+0.18 (0.14%)
At close: Nov 26, 2025, 4:00 PM EST
129.34
-1.10 (-0.84%)
After-hours: Nov 26, 2025, 5:24 PM EST
Novartis AG Employees
Novartis AG had 75,883 employees as of December 31, 2024. The number of employees decreased by 174 or -0.23% compared to the previous year.
Employees
75,883
Change (1Y)
-174
Growth (1Y)
-0.23%
Revenue / Employee
$742,880
Profits / Employee
$189,674
Market Cap
251.09B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 75,883 | -174 | -0.23% |
| Dec 31, 2023 | 76,057 | -25,646 | -25.22% |
| Dec 31, 2022 | 101,703 | -2,620 | -2.51% |
| Dec 31, 2021 | 104,323 | -1,471 | -1.39% |
| Dec 31, 2020 | 105,794 | 1,880 | 1.81% |
| Dec 31, 2019 | 103,914 | -21,247 | -16.98% |
| Dec 31, 2018 | 125,161 | 3,564 | 2.93% |
| Dec 31, 2017 | 121,597 | 3,204 | 2.71% |
| Dec 31, 2016 | 118,393 | -307 | -0.26% |
| Dec 31, 2015 | 118,700 | -14,713 | -11.03% |
| Dec 31, 2014 | 133,413 | -2,283 | -1.68% |
| Dec 31, 2013 | 135,696 | 7,972 | 6.24% |
| Dec 31, 2012 | 127,724 | 4,038 | 3.26% |
| Dec 31, 2011 | 123,686 | 4,268 | 3.57% |
| Dec 31, 2010 | 119,418 | 19,584 | 19.62% |
| Dec 31, 2009 | 99,834 | 3,117 | 3.22% |
| Dec 31, 2008 | 96,717 | -1,483 | -1.51% |
| Dec 31, 2007 | 98,200 | -2,535 | -2.52% |
| Dec 31, 2006 | 100,735 | 9,735 | 10.70% |
| Dec 31, 2005 | 91,000 | 9,600 | 11.79% |
| Dec 31, 2004 | 81,400 | 2,859 | 3.64% |
| Dec 31, 2003 | 78,541 | 5,664 | 7.77% |
| Dec 31, 2002 | 72,877 | 2,557 | 3.64% |
| Dec 31, 2001 | 70,320 | 1,252 | 1.81% |
| Dec 31, 2000 | 69,068 | -13,391 | -16.24% |
| Dec 31, 1999 | 82,459 | -3,376 | -3.93% |
| Dec 31, 1998 | 85,835 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
NVS News
- 23 hours ago - Why Novartis Stock Topped the Market Today - The Motley Fool
- 1 day ago - FDA OKs Novartis SMA Treatment As First Gene Therapy Option For Kids, Teens And Adults - Benzinga
- 1 day ago - Novartis plans to cut up to 550 jobs at Swiss facility - Reuters
- 1 day ago - Novartis data underscore pioneering scientific innovation in Hematology and Oncology at ASH and SABCS - GlobeNewsWire
- 1 day ago - Muscular Dystrophy Association Calls FDA Approval of Novartis' Itvisma (onasemnogene abeparvovec-brve) a Major Step Forward for the Spinal Muscular Atrophy Community - GlobeNewsWire
- 2 days ago - FDA approves Novartis' gene therapy for rare muscle disorder - Reuters
- 2 days ago - Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA) - GlobeNewsWire
- 5 days ago - Novartis AG (NVS) Shareholder/Analyst Call Transcript - Seeking Alpha